Bicocca Open Archive

Logo unimib boa
LAPADULA, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.122
AS - Asia 6.843
EU - Europa 4.788
SA - Sud America 1.175
AF - Africa 116
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 5
Totale 22.055
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.863
SG - Singapore 2.541
HK - Hong Kong 1.246
VN - Vietnam 1.242
CN - Cina 1.171
RU - Federazione Russa 992
BR - Brasile 944
IT - Italia 930
SE - Svezia 656
IE - Irlanda 570
DE - Germania 563
GB - Regno Unito 219
UA - Ucraina 175
CA - Canada 142
AT - Austria 132
FR - Francia 131
ID - Indonesia 124
FI - Finlandia 119
IN - India 106
KR - Corea 92
MX - Messico 90
AR - Argentina 78
NL - Olanda 66
TR - Turchia 62
ZA - Sudafrica 58
BD - Bangladesh 53
RO - Romania 44
EC - Ecuador 42
PL - Polonia 41
JP - Giappone 37
IQ - Iraq 32
DK - Danimarca 30
ES - Italia 30
CO - Colombia 28
CZ - Repubblica Ceca 22
VE - Venezuela 18
BE - Belgio 16
KE - Kenya 16
PE - Perù 16
PY - Paraguay 16
CL - Cile 15
IR - Iran 15
UZ - Uzbekistan 15
LT - Lituania 13
MA - Marocco 13
PK - Pakistan 12
SA - Arabia Saudita 11
UY - Uruguay 11
AL - Albania 10
PH - Filippine 10
AE - Emirati Arabi Uniti 8
BO - Bolivia 6
CH - Svizzera 6
EG - Egitto 6
HN - Honduras 6
IL - Israele 6
JO - Giordania 6
KZ - Kazakistan 6
NP - Nepal 6
PA - Panama 6
AZ - Azerbaigian 5
LB - Libano 5
MY - Malesia 5
TN - Tunisia 5
AU - Australia 4
BH - Bahrain 4
CR - Costa Rica 4
EE - Estonia 4
ET - Etiopia 4
GE - Georgia 4
OM - Oman 4
AM - Armenia 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
HU - Ungheria 3
JM - Giamaica 3
LV - Lettonia 3
PT - Portogallo 3
SN - Senegal 3
TW - Taiwan 3
AO - Angola 2
BG - Bulgaria 2
BY - Bielorussia 2
EU - Europa 2
KW - Kuwait 2
LU - Lussemburgo 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
SY - Repubblica araba siriana 2
TG - Togo 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BN - Brunei Darussalam 1
BW - Botswana 1
CI - Costa d'Avorio 1
GD - Grenada 1
GR - Grecia 1
GT - Guatemala 1
GY - Guiana 1
IS - Islanda 1
Totale 22.046
Salva come PNG Salva come JPEG
Città #
Singapore 1.531
Hong Kong 1.246
Ann Arbor 987
Ashburn 767
Fairfield 590
Dublin 554
Woodbridge 491
Chandler 466
Dallas 434
Houston 423
Ho Chi Minh City 356
Frankfurt am Main 346
New York 328
Hanoi 308
Wilmington 290
Santa Clara 258
Milan 238
Princeton 230
Hefei 227
Los Angeles 226
Seattle 223
Cambridge 196
Jacksonville 195
Beijing 172
Dearborn 130
Chicago 121
Moscow 119
Altamura 111
Lawrence 111
Jakarta 109
Buffalo 89
The Dalles 88
Vienna 86
Seoul 85
Paris 80
Shanghai 73
São Paulo 73
San Diego 64
Nanjing 53
Munich 49
Nuremberg 49
Dong Ket 44
Galati 43
London 42
Haiphong 39
Rome 39
Da Nang 38
Helsinki 37
Lachine 37
Tokyo 36
Warsaw 36
Montreal 32
Biên Hòa 31
Johannesburg 31
Lappeenranta 31
Andover 30
Boardman 30
Rio de Janeiro 30
Guangzhou 29
Kent 27
Quận Bình Thạnh 26
Salt Lake City 26
Brooklyn 24
Mexico City 24
Pune 24
Brasília 23
Ha Long 23
Hải Dương 23
Poplar 23
Stockholm 23
Toronto 22
Chennai 20
Curitiba 20
Palermo 20
Atlanta 19
Denver 19
Vũng Tàu 19
Fremont 18
Phoenix 18
Thái Nguyên 18
Amsterdam 17
Belo Horizonte 17
Cuauhtémoc 17
Falls Church 17
Ninh Bình 17
Norwalk 17
Ottawa 17
Shenyang 17
Bogotá 15
Brussels 15
Busto Arsizio 15
Changsha 15
Columbus 15
Hebei 15
Tampa 15
Tashkent 15
Brno 14
Can Tho 14
Council Bluffs 14
Monza 14
Totale 13.978
Salva come PNG Salva come JPEG
Nome #
Characterizing non-tuberculous mycobacteria infection in bronchiectasis 369
Unexpected HBV reactivation following discontinuation of antiviral prophylaxis in immunosuppressed subjects with previous HBV exposure 353
Remdesivir use in patients requiring mechanical ventilation due to COVID-19 329
The high volume of patients admitted during the SARS-CoV-2 pandemic has an independent harmful impact on in-hospital mortality from COVID-19 278
Caratteristiche di una coorte di pazienti con co-infezione HIV/HCV: i dati dell’Ambulatorio di Malattie Infettive dell’Ospedale San Gerardo di Monza 276
Brief Report: Peripheral Monocyte/Macrophage Phenotypes Associated with the Evolution of Cognitive Performance in HIV-Infected Patients 274
Effectiveness of dolutegravir-based vs boosted darunavir-based first-line 3-drug regimens in people with HIV with advanced disease: a trial emulation 270
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 265
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 256
Transaminase Decrease Upon Switch From TDF to TAF in PWH Is Modulated by HBV Status 255
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 253
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 253
HPV 16 and 18 contribute to development of anal dysplasia in HIV infection irrespective of gender and sexual orientation 251
Infezione disseminata da Mycobacterium avium complex con batteriemia persistente in un paziente AIDS-presenter [Disseminated Mycobacterium avium complex infection with persistent bacteremia in an AIDS-presenter patient] 249
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting 244
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 242
miRNA Expression Profiling in Subcutaneous Adipose Tissue of Monozygotic Twins Discordant for HIV Infection: Validation of Differentially Expressed miRNA and Bioinformatic Analysis 242
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 236
Remission of low-grade lymphomatoid granulomatosis with extensive pulmonary involvement following immune restoration via antiretroviral therapy in a newly diagnosed HIV patient 235
ECMO: An alternative support for acute respiratory failure caused by tuberculosis? 231
Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients 229
Hepatitis B core antibody positivity is not associated with risk of transaminase elevation following switch to dual antiretroviral therapy 221
Regaining virological suppression in a woman living with a six-class resistant HIV by combining injectable antiretroviral drugs guided by genotypic and phenotypic tests 219
Unmasking tuberculosis in the era of antiretroviral treatment 212
Neurocognitive Impairment in HIV-Infected Naïve Patients with Advanced Disease: The Role of Virus and Intrathecal Immune Activation 209
Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: Relapse or late IRIS? 208
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 203
Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice 202
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study 201
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 198
Nontuberculous Mycobacteria in Noncystic Fibrosis Bronchiectasis 196
Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances 196
Influence of hospitalization upon diagnosis on the risk of tuberculosis clustering 193
Malassorbimento intestinale della terapia antiretrovirale in un paziente affetto da AIDS e micobatteriosi atipica disseminata 191
Mycobacterium tuberculosis Beijing family: Analysis of the epidemiological and clinical factors associated with an emerging lineage in the urban area of Milan 187
Influence of efavirenz and 8-hydroxy-efavirenz plasma levels on cognition and central nervous system side effects 186
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 186
Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort 184
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: A prospective international cohort study 184
Determinants of patient and health care services delays for tuberculosis diagnosis in Italy: A cross-sectional observational study 184
High-risk HPV genotypes are associated with anal cytologic abnormalities but not with malignant histological lesions in a cohort of people with HIV (PWH) 183
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 183
Beware of biases in observational studies on anti-spike monoclonal antibodies 178
COVID-19 Mortality and Stress to the Hospital System From High Patient Load 177
Clinical and laboratory predictors of mpox severity and duration: an Italian multicentre cohort study (mpox-Icona) 172
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 168
Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy 167
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013 166
Risk of severe non AIDS events is increased among patients unable to increase their CD4 + T-cell counts >200+/μl despite effective HAART 163
A case of mild pulmonary disease due to Mycobacterium shimoidei with a favorable outcome 160
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 160
Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment 159
Long-term durability of dolutegravir + darunavir/cobicistat dual regimen in highly antiretroviral-experienced people living with HIV (DoDaco study) 157
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure 157
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 154
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort) 153
To the editor 152
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 152
Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: The D:A:D study 150
Anti-spike antibody level is associated with the risk of clinical progression among subjects hospitalized with COVID-19 pneumonia: results from a retrospective cohort study 148
Knowledge, Use, and Misuse of Self-Prescribed Doxycycline Postexposure Prophylaxis in a Community-Based Preexposure Prophylaxis Service 147
Long pentraxin 3 (PTX3) levels predict death, intubation and thrombotic events among hospitalized patients with COVID-19 147
Monoclonal antibodies against SARS-CoV-2 to prevent COVID-19 worsening in a large multicenter cohort 146
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 142
CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load 139
Associations between immune depression and cardiovascular events in HIV infection 137
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 133
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 133
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort 132
COVID-19 Infection among Incarcerated Individuals and Prison Staff in Lombardy, Italy, March 2020 to February 2021 132
Imported ciprofloxacin-resistant Neisseria meningitidis 132
Pregnant women living with HIV: the experience of IRCCS San Gerardo dei Tintori 131
Do we Still Need Eligibility Criteria to Recommend PrEP? Impact of National Prescribing Requirements on Retention in Care and Sexually Transmitted Infections Acquisition 128
Awake Prone Positioning in Adults With COVID-19 An Individual Participant Data Meta-Analysis 127
Unmasked tuberculosis or lymphoma in late AIDS presenters: A difficult differential diagnosis 127
Behavioural survey and street-based HIV and HCV rapid testing programme among transgender sex workers 127
Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study 126
Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: A comparison of the D: A: D CVD risk equation and general population CVD risk equations 125
Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration 124
Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress? 124
Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort 123
Predictors of AIDS-defining events among advanced naïve patients after HAART 123
Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: A longitudinal study 122
Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: The D: A: D study 121
Hepatitis C virus antibody-positive patients with HIV infection have a high risk of insulin resistance: A cross-sectional study 120
In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry 119
Mpox Virus in the Pharynx of Men Having Sex with Men: A Case Series 118
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 117
Long-term durability of dolutegravir plus darunavir/cobicistat dual regimen in highly antiretroviral-experienced people with HIV (DoDaco study) 117
Heavily treatment-experienced persons living with HIV currently in care in Italy: characteristics, risk factors, and therapeutic options-the ICONA Foundation cohort study 114
3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir 114
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort 113
Compassionate Use of Remdesivir in Children With Severe COVID-19 113
Late-Onset Combined Immunodeficiency presenting with Progressive Multifocal Leukoencephalopathy and associated Immune Reconstitution Inflammatory Syndrome 112
Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the italian atazanavir expanded access program and master cohorts 112
Prolonged higher dose methylprednisolone vs. conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS) 112
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 111
Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts >= 200 cells/mm(3) 111
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 110
Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors 108
Totale 17.578
Salva come PNG Salva come JPEG
Categoria #
all - tutte 88.232
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 88.232
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021763 0 0 0 0 0 67 84 125 118 131 81 157
2021/20221.481 68 88 368 136 63 111 31 113 58 72 125 248
2022/20232.134 264 585 198 156 141 377 19 114 178 28 50 24
2023/20241.798 62 52 87 47 216 459 356 67 181 54 33 184
2024/20256.379 279 718 595 216 430 244 376 151 458 798 600 1.514
2025/20266.541 1.490 964 1.186 1.321 1.417 163 0 0 0 0 0 0
Totale 22.798